Growth-inhibitory effect of STI571 on cells transformed by theCOL1A1/PDGFB rearrangement
Open Access
- 28 February 2001
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 92 (3) , 354-360
Abstract
Dermatofibrosarcoma protuberans (DP) is a skin tumor of intermediate malignancy characterized by high recurrence rates, for which surgical excision is the main therapy. All DP cases carry a specific t(17;22) translocation, resulting in a COL1A1/PDGFB rearrangement. The subsequently deregulated production of PDGFB generates autocrine stimulation of PDGFrβ, leading to malignant transformation. Using NIH‐3T3 cells transformed by the COL1A1/PDGFB rearrangement (5A cell line), we explored the possibility of blocking the PDGFB autocrine loop, both in vitro and in vivo, using STI571, an inhibitor of the PDGF receptor and of ABL kinase activity. The presence of small amounts of serum in the culture medium was required for the in vitro growth and morphological transformation of 5A cells. In the presence of STI571, the growth rate was reduced and the associated transformed phenotype changed to a flattened one. This effect could be reversed on removal of the inhibitor. The growth rate of tumors induced by 5A cells in nude mice was reduced by STI571 administration. Interestingly, this effect was also evident on pre‐existing tumors, but no tumor eradication was observed. This is consistent with the reversible effects of the inhibitor observed in vitro but differs from the eradication effect of STI571 on BCR‐ABL–induced tumors. Our data indicate that STI571 might be a candidate compound for the pharmacological treatment of DP and demonstrate that the same compound may act in different ways (cytotoxic vs. cytostatic), according to the specificity of the inhibited tyrosine kinase, namely, ABL or PDGFrβ.Keywords
This publication has 16 references indexed in Scilit:
- NF-κB is a target of AKT in anti-apoptotic PDGF signallingNature, 1999
- Pretreatment with intralesional hyaluronidase prior to excision of dermatofibrosarcoma protuberansCancer Letters, 1998
- Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberansOncogene, 1998
- The Role of Radiation Therapy in the Management of Dermatofibrosarcoma ProtuberansInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces ApoptosisBlood Cells, Molecules, and Diseases, 1997
- Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastomaNature Genetics, 1997
- Platelet-Derived Growth Factor Is an Autocrine Stimulator for the Growth and Survival of Human Esophageal Carcinoma Cell LinesExperimental Cell Research, 1996
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangementCytogenetic and Genome Research, 1996
- Ring chromosomes in dermatofibrosarcoma protuberans contain chromosome 17 sequences: Fluorescence in situ hybridizationCancer Genetics and Cytogenetics, 1993